Viewing Study NCT07260760


Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2025-12-26 @ 12:31 AM
Study NCT ID: NCT07260760
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-03
First Post: 2025-11-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
Sponsor: Qianfoshan Hospital
Organization:

Study Overview

Official Title: Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Ischemic strok
Brief Summary: This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment (TOAST )classification.
Detailed Description: A comprehensive evaluation of commonly used clinical neuroprotective drugs was conducted, analyzing their practical application value in acute ischemic stroke treatment across six dimensions: safety, efficacy, cost-effectiveness, innovation, appropriateness, and accessibility. In a real-world clinical setting, this prospective observational study design primarily evaluates the association between edaravone and dexrazoxane usage and the efficacy and safety outcomes in patients with mild-to-moderate ischemic stroke, while conducting subgroup analyses based on different Trial of Org 10172 in Acute Stroke Treatment (TOAST )classifications.

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: